



**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-A**

**FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES  
PURSUANT TO SECTION 12(b) OR 12(g) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**CADENCE PHARMACEUTICALS, INC.**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**  
(State of Incorporation or Organization)

**41-2142317**  
(I.R.S. Employer  
Identification No.)

**12481 High Bluff Drive, Suite 200**  
**San Diego, California**  
(Address of Principal  
Executive Offices)

**92130**  
(Zip Code)

Securities to be registered pursuant to Section 12(b) of the Act:

Title of Each Class  
to be so Registered

Common Stock, par value \$0.0001 per share

Name of Each Exchange on Which  
Each Class is to be Registered

The NASDAQ Stock Market LLC

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), please check the following box.

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), please check the following box.

Securities Act registration statement file number to which this form relates:333-135821

Securities to be registered pursuant to Section 12(g) of the Act:

None  
(Title of Class)

## INFORMATION REQUIRED IN REGISTRATION STATEMENT

### **Item 1. Description of Registrant's Securities to be Registered.**

A description of the Common Stock, par value \$0.0001 per share ("Common Stock"), of Cadence Pharmaceuticals, Inc., a Delaware corporation (the "Registrant"), to be registered hereunder is contained under the caption "Description of Capital Stock" in the Prospectus that constitutes part of the Registrant's Registration Statement on Form S-1 (File No. 333-135821) initially filed with the Securities and Exchange Commission on July 17, 2006, as amended from time to time, and is incorporated herein by reference.

### **Item 2. Exhibits.**

Under the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed, because no other securities of the Registrant are registered on The NASDAQ Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Exchange Act.

---

**SIGNATURE**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

Dated: October 19, 2006

CADENCE PHARMACEUTICALS, INC.

By: /s/ Theodore R. Schroeder

Name: Theodore R. Schroeder

Title: President and Chief Executive Officer